Journal article

Distinct clinical and pathological features are associated with the BRAF (T1799A(V600E)) mutation in primary melanoma

Wendy Liu, John W Kelly, Melanie Trivett, William K Murray, John P Dowling, Rory Wolfe, Graham Mason, Jill Magee, Christopher Angel, Alexander Dobrovic, Grant A McArthur

JOURNAL OF INVESTIGATIVE DERMATOLOGY | NATURE PUBLISHING GROUP | Published : 2007

Abstract

The BRAF(T1799A) mutation encodes BRAF(V600E) that leads to activation of the mitogen-activated protein kinase pathway. This study aimed to assess the clinico-pathological features of primary invasive melanomas containing the BRAF(T1799A) mutation. Patients (n=251) with invasive primary melanomas from Australia were interviewed and examined with respect to their melanoma characteristics and risk factors. Independent review of pathology, allele-specific PCR for the BRAF(T1799A) mutation, immunohistochemical staining with Ki67, and phospho-histone-H3 (PH3) were performed. The BRAF(T1799A) mutation was found in 112 (45%) of the primary melanomas. Associations with the BRAF(T1799A) mutation (P<0..

View full abstract